Search

Xuena Wang Phones & Addresses

  • Snoqualmie, WA
  • Thousand Oaks, CA
  • 4516 Red Spruce Ln, Manlius, NY 13104
  • Stony Brook, NY

Work

Company: Amgen Oct 2008 Position: Biostatistics manager

Education

School / High School: State University of New York at Stony Brook 2000 to 2004

Skills

Biostatistics • Sas • R • Survival Analysis • Statistical Modeling • Clinical Trials • Statistical Programming • Oncology • Sas Programming • Cro • Data Analysis • Clinical Development

Industries

Biotechnology

Resumes

Resumes

Xuena Wang Photo 1

Director Of Biostatistics

View page
Location:
P/O Box 1027, Millbrook, AL
Industry:
Biotechnology
Work:
Amgen since Oct 2008
Biostatistics Manager

Quintiles Jun 2006 - Oct 2008
Sr. Biostatistician
Education:
State University of New York at Stony Brook 2000 - 2004
University of Science and Technology of China 1993 - 2000
MS, Statistics
Skills:
Biostatistics
Sas
R
Survival Analysis
Statistical Modeling
Clinical Trials
Statistical Programming
Oncology
Sas Programming
Cro
Data Analysis
Clinical Development

Publications

Us Patents

Method And System For Detecting Discriminatory Data Patterns In Multiple Sets Of Data

View page
US Patent:
20050022168, Jan 27, 2005
Filed:
Jun 14, 2004
Appl. No.:
10/868387
Inventors:
Wei Zhu - Stony Brook NY, US
Xuena Wang - Stony Brook NY, US
John Kovach - Setauket NY, US
International Classification:
G06F009/44
US Classification:
717124000
Abstract:
A comprehensive analysis procedure for analyzing and comparing multiple sets of data to detect hidden discriminatory data patterns. The inventive procedure identifies a best subset of markers for optimal discrimination between two or more sets of data. A point-wise test on two or more sets of data is performed to calculate test statistic values and to generate a statgram, a two- or higher- dimensional map of the test statistic values along the range of data. A threshold is then determined for isolating critical regions of the statgram at each significance level to provide candidate markers. A subset of markers from the candidate markers is then selected to discriminate among the sets of data. The two or more sets of data are classified using the subset of markers.

Method And System For Detecting Discriminatory Data Patterns In Multiple Sets Of Data

View page
US Patent:
20130238251, Sep 12, 2013
Filed:
Apr 18, 2013
Appl. No.:
13/865712
Inventors:
Xuena WANG - Stony Brook NY, US
John S. KOVACH - Setauket NY, US
Assignee:
The Research Foundation for The State University of New York - Albany NY
International Classification:
G06F 17/18
US Classification:
702 19, 702179
Abstract:
A comprehensive analysis procedure for analyzing and comparing multiple sets of data to detect hidden discriminatory data patterns. The inventive procedure identifies a best subset of markers for optimal discrimination between two or more sets of data. A point-wise test on two or more sets of data is performed to calculate test statistic values and to generate a statgram, a two- or higher-dimensional map of the test statistic values along the range of data. A threshold is then determined for isolating critical regions of the statgram at each significance level to provide candidate markers. A subset of markers from the candidate markers is then selected to discriminate among the sets of data. The two or more sets of data are classified using the subset of markers.

Method Of Treating Idiopathic Thrombocytopenia Purpura (Itp) With Romiplostim

View page
US Patent:
20200360480, Nov 19, 2020
Filed:
Dec 6, 2018
Appl. No.:
16/771641
Inventors:
- Thousand Oaks CA, US
James BUSSEL - New York NY, US
Melissa EISEN - Oak Park CA, US
Nancy CARPENTER - Carterton, Oxfordshire, GB
Xuena WANG - Manlius NY, US
Susanna MAC - Agoura Hills CA, US
Assignee:
AMGEN INC. - Thousand Oaks CA
International Classification:
A61K 38/19
A61P 7/00
Abstract:
The present invention concerns a method of treating idiopathic thrombocytopenia purpura (ITP) in a patient having ITP, which comprises: (a) administering romiplostim weekly to the patient; (b) increasing the weekly dose until a platelet count of at least about 50 to 200×10/L is reached; (c) decreasing the weekly dose of romiplostim if the platelet count remains ≥200×10/L for two consecutive weeks; (d) discontinuing romiplostim if the platelet count has remained ≥200×10/L for two consecutive weeks when the weekly dose is 1 μg/kg or the platelet count is ≥400×10/L; and (e) if a platelet count ≥200×10/L is reached within the first 4 to 12 weeks of treatment, maintaining a treatment-free period of at least about 24 weeks during which the patient receives no romiplostim.
Xuena T Wang from Snoqualmie, WA, age ~47 Get Report